Vitamin B1 (thiamine) and dementia

Annals of the New York Academy of Sciences

Volumn 1367, Issue 1, 2016, Pages 21-30

  Gibson, Gary E ^a,b   Hirsch, Joseph A ^c   Fonzetti, Pasquale ^c   Jordan, Barry D ^c   Cirio, Rosanna T ^c   Elder, Jessica ^a,b  

^a FEIL FAMILY BRAIN AND MIND RESEARCH INSTITUTE   (United States)

^b BURKE MEDICAL RESEARCH INSTITUTE   (United States)

^c BURKE REHABILITATION HOSPITAL   (United States)

Author keywords

Alzheimer's disease; Glucose metabolism; Mitochondria; Thiamine; Vitamin B1

Indexed keywords

BENFOTIAMINE; FURSULTIAMINE; GLUCOSE; SULBUTIAMINE; TAU PROTEIN; THIAMINE; THIAMINE DERIVATIVE;

ACETYLCHOLINE RELEASE; ALZHEIMER DISEASE; AMNESIA; AMYLOID PLAQUE; ARTICLE; ATTENTION; AVOIDANCE BEHAVIOR; BRAIN METABOLISM; CITRIC ACID CYCLE; COGNITION; COGNITIVE DEFECT; EMOTIONAL DISORDER; EPISODIC MEMORY; EXECUTIVE FUNCTION; GLUCOSE BRAIN LEVEL; GLUCOSE METABOLISM; GLYCOLYSIS; HUMAN; KORSAKOFF PSYCHOSIS; MENTAL DISEASE; MULTICENTER STUDY (TOPIC); NEUROCHEMISTRY; NEUROTRANSMISSION; NONHUMAN; OXIDATIVE STRESS; PASSIVE AVOIDANCE; PERIPHERAL NEUROPATHY; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); THIAMINE DEFICIENCY; WERNICKE KORSAKOFF SYNDROME; WORKING MEMORY; ANIMAL; DEMENTIA; METABOLISM; PROCEDURES;

ALZHEIMER DISEASE; ANIMALS; DEMENTIA; GLUCOSE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THIAMINE; THIAMINE DEFICIENCY;

EID: 84960924315     PISSN: 00778923     EISSN: 17496632     Source Type: Journal    
DOI: 10.1111/nyas.13031     Document Type: Article

References (56)

1. Victor, M., R. Adams & G.H. Collins . 1989. The Wernicke-Korsakoff Syndrome. Philadelphia: F.A. Davis.
2. Williams, R.D. et al. 1940. Observations on induced thiamine (vitamin B1) deficiency in man. Arch. Intern. Med. 66: 785-799.
3. Kopelman, M. 1991. Frontal dysfunction and memory deficits in the alcoholic Korsakoff syndrome and Alzheimer-type dementia. Brain 114: 117-137.
4. Dubois, B. et al. 2010. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol. 9: 1118-1127.
5. Sperling, R.A. et al. 2011. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 7: 280-292.
6. Salloway, S. & R. Sperling . 2015. Understanding conflicting neuropathological findings in patients clinically diagnosed as having Alzheimer dementia. JAMA Neurol. 72: 1106-1108.
7. Monsell, S.E., et al. 2015. Characterizing apolipoprotein E ε4 carriers and noncarriers with the clinical diagnosis of mild to moderate Alzheimer dementia and minimal β-amyloid peptide plaques. JAMA Neurol. 72: 1124-1131.
8. Calingasan, N.Y., K. Uchida & G.E. Gibson . 1999. Protein-bound acrolein. J. Neurochem. 72: 751-756.
9. Pratico, D. et al. 2001. Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. J. Neurosci. 21: 4183-4187.
10. Perrin, R.J., A.M. Fagan & D.M. Holtzman . 2009. Multimodal techniques for diagnosis and prognosis of Alzheimer's disease. Nature 461: 916-922.
11. Furst, A.J. et al. 2012. Cognition, glucose metabolism and amyloid burden in Alzheimer's disease. Neurobiol. Aging 33: 215-225.
12. Reed, L.J. et al. 2003. FDG-PET findings in the Wernicke-Korsakoff syndrome. Cortex 39: 1027-1045.
13. Hata, T. et al. 1987. Three-dimensional mapping of local cerebral perfusion in alcoholic encephalopathy with and without Wernicke-Korsakoff syndrome. J. Cereb. Blood Flow Metab. 7: 35-44.
14. Gibson, G.E. et al. 1988. Reduced activities of thiamine-dependent enzymes in the brains and peripheral tissues of patients with Alzheimer's disease. Arch. Neurol. 45: 836-840.
15. Gangolf, M. et al. 2010. Thiamine status in humans and content of phosphorylated thiamine derivatives in biopsies and cultured cells. PLoS One 5: e13616.
16. Mason, H.L. & R.D. Williams . 1942. The urinary excretion of thiamine as an index of the nutritional level: assessment of the value of a test dose. J. Clin. Invest. 21: 247-255.
17. Gold, M., R. Hauser & M. Chen . 1998. Plasma thiamine deficiency associated with Alzheimer's disease but not Parkinson's disease. Metab. Brain Dis. 13: 43-53.
18. Bubber, P. et al. 2005. Mitochondrial abnormalities in Alzheimer brain: mechanistic implications. Ann. Neurol. 57: 695-703.
19. Nakagawasai, O. et al. 2000. Immunohistochemical estimation of brain choline acetyltransferase and somatostatin related to the impairment of avoidance learning induced by thiamine deficiency. Brain Res. Bull. 52: 189-196.
20. Langlais, P.J. & L.M. Savage . 1995. Thiamine deficiency in rats produces cognitive and memory deficits on spatial tasks that correlate with tissue loss in diencephalon, cortex and white matter. Behav. Brain Res. 68: 75-89.
21. Langlais, P.J., R.J. Mandel & R.G. Mair . 1992. Diencephalic lesions, learning impairments, and intact retrograde memory following acute thiamine deficiency in the rat. Behav. Brain Res. 48: 177-185.
22. Carvalho, F.M. et al. 2006. Thiamine deficiency decreases glutamate uptake in the prefrontal cortex and impairs spatial memory performance in a water maze test. Pharmacol. Biochem. Behav. 83: 481-489.
23. Anderson, C.D. et al. 1986. Learning impairments after 6-OHDA treatment: a comparison with the effects of thiamine deficiency. Behav. Brain Res. 21: 21-27.
24. Mair, R.G. et al. 1985. Thiamine deficiency depletes cortical norepinephrine and impairs learning processes in the rat. Brain Res. 360: 273-284.
25. Zhao, N. et al. 2008. Impaired hippocampal neurogenesis is involved in cognitive dysfunction induced by thiamine deficiency at early pre-pathological lesion stage. Neurobiol. Dis. 29: 176-185.
26. Peters, R. 1936. The biochemical lesion in vitamin B1 deficiency: application of modern biochemical analysis in its diagnosis. Lancet 227: 1161-1165.
27. Freeman, G.B., P.E. Nielsen & G.E. Gibson . 1987. Effect of age on behavioral and enzymatic changes during thiamin deficiency. Neurobiol. Aging 8: 429-434.
28. Barclay, L.L., G.E. Gibson & J.P. Blass . 1981. Impairment of behavior and acetylcholine metabolism in thiamine deficiency. J. Pharmacol. Exp. Ther. 217: 537-543.
29. Langlais, P.J. & S.X. Zhang . 1993. Extracellular glutamate is increased in thalamus during thiamine deficiency-induced lesions and is blocked by MK-801. J. Neurochem. 61: 2175-2182.
30. Hazell, A.S., R.F. Butterworth & A.M. Hakim . 1993. Cerebral vulnerability is associated with selective increase in extracellular glutamate concentration in experimental thiamine deficiency. J. Neurochem. 61: 1155-1158.
31. Ke, Z.-J. & G.E. Gibson . 2004. Selective response of various brain cell types during neurodegeneration induced by mild impairment of oxidative metabolism. Neurochem. Int. 45: 361-369.
32. Karuppagounder, S.S. et al. 2009. Thiamine deficiency induces oxidative stress and exacerbates the plaque pathology in Alzheimer's mouse model. Neurobiol. Aging 30: 1587-1600.
33. Zhang, Q., et al. 2011. Thiamine deficiency increases β-secretase activity and accumulation of β-amyloid peptides. Neurobiol. Aging 32: 42-53.
34. Pan, X. et al. 2010. Powerful beneficial effects of benfotiamine on cognitive impairment and {beta}-amyloid deposition in amyloid precursor protein/presenilin-1 transgenic mice. Brain 133: 1342-1351.
35. Elie, I.-G. et al. 2015. Nonalcoholic thiamine-related encephalopathy (Wernicke-Korsakoff syndrome) among inpatients with cancer: a series of 18 cases. Psychosomatics 57: 71-81.
36. Babaei-Jadidi, R. et al. 2003. Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine. Diabetes 52: 2110-2120.
37. Kennedy, A.R. 2001. The potential role of thiamine in the pathogenesis and treament of Alzheimer's disease. M.S. dissertation. University of Manitoba, Winnipeg.
38. Blass, J.P. & G.E. Gibson . 1977. Abnormality of a thiamine-requiring enzyme in patients with Wernicke-Korsakoff syndrome. N. Engl. J. Med. 297: 1367-1370.
39. Volvert, M.-L. et al. 2008. Benfotiamine, a synthetic S-acyl thiamine derivative, has different mechanisms of action and a different pharmacological profile than lipid-soluble thiamine disulfide derivatives. BMC Pharmacol. 8: 10.
40. Pincus, J.H., G.B. Solitare & J.R. Cooper . 1976. Thiamine triphosphate levels and histopathology. Correlation in Leigh disease. Arch. Neurol. 33: 759-763.
41. Calingasan, N.Y. et al. 2000. Vascular factors are critical in selective neuronal loss in an animal model of impaired oxidative metabolism. J Neuropathol. Exp. Neurol. 59: 207-217.
42. Calingasan, N.Y. et al. 1998. Induction of nitric oxide synthase and microglial responses precede selective cell death induced by chronic impairment of oxidative metabolism. Am. J. Pathol. 153: 599-610.
43. Berrone, E. et al. 2006. Regulation of intracellular glucose and polyol pathway by thiamine and benfotiamine in vascular cells cultured in high glucose. J. Biol. Chem. 281: 9307-9313.
44. Gibson, G.E. et al. 2013. Abnormal thiamine-dependent processes in Alzheimer's disease. Lessons from diabetes. Mol. Cell. Neurosci. 55: 17-25.
45. Bitsch, R. et al. 1991. Bioavailability assessment of the lipophilic benfotiamine as compared to a water-soluble thiamin derivative. Ann. Nutr. Metab. 35: 292-296.
46. Schreeb, K.H. et al. 1997. Comparative bioavailability of two vitamin B1 preparations: benfotiamine and thiamine mononitrate. Eur. J. Clin. Pharmacol. 52: 319-320.
47. Perez-Pineiro, R. et al. 2011. The prion protein binds thiamine. FEBS J. 278: 4002-4014.
48. Hirsch, J.A. & G.E. Gibson . 1984. Thiamin antagonists and the release of acetylcholine and norepinephrine from brain slices. Biochem. Pharmacol. 33: 2325-2327.
49. Huang, H.-M., H.-L. Chen & G. Gibson . 2010. Thiamine and oxidants interact to modify cellular calcium stores. Neurochem. Res. 35: 2107-2116.
50. Mkrtchyan, G. et al. 2015. Molecular mechanisms of the non-coenzyme action of thiamin in brain: biochemical, structural and pathway analysis. Sci. Rep. 5: 12583.
51. Blass, J.P. et al. 1988. Thiamine and Alzheimer's disease: a pilot study. Arch. Neurol. 45: 833-835.
52. Nolan, K.A. et al. 1991. A trial of thiamine in Alzheimer's disease. Arch. Neurol. 48: 81-83.
53. Meador, K. et al. 1993. Preliminary findings of high-dose thiamine in dementia of Alzheimer's type. J. Geriatr. Psychiatry Neurol. 6: 222-229.
54. Mimori, Y., H. Katsuoka & S. Nakamura . 1996. Thiamine therapy in Alzheimer's disease. Metab. Brain Dis. 11: 89-94.
55. Ollat, H. et al. 2007. Effects of the association of sulbutiamine with an acetylcholinesterase inhibitor in early stage and moderate Alzheimer disease. Encephale 33: 211-215.
56. Karuppagounder, S.S. et al. 2009. Dietary supplementation with resveratrol reduces plaque pathology in a transgenic model of Alzheimer's disease. Neurochem. Int. 54: 111-118.